Tolerance induction by "megadose" hematopoietic transplants: donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture.
about
Haploidentical Stem Cell Transplantation in Adult Haematological MalignanciesModern approaches to HLA-haploidentical blood or marrow transplantationAdvances in haplo-identical stem cell transplantation in adults with high-risk hematological malignanciesThe role of gamma delta T cells in haematopoietic stem cell transplantationThe role of megadose CD34+ progenitor cells in the treatment of leukemia patients without a matched donor and in tolerance induction for organ transplantation.Induction of tolerance to bone marrow allografts by donor-derived host nonreactive ex vivo-induced central memory CD8 T cells.Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor.A clinical trial combining donor bone marrow infusion and heart transplantation: intermediate-term resultsGenetically haploidentical stem cell transplantation for acute leukemia.Allogeneic transplantation across the HLA barriers.Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation.Nonmyeloablative allogeneic stem cell transplantation using alternative donors.Murine anti-third-party central-memory CD8(+) T cells promote hematopoietic chimerism under mild conditioning: lymph-node sequestration and deletion of anti-donor T cells.Megadose CD34+ hemopoietic stem cell transplantation for patients with high risk acute myeloid leukemia who have no HLA matched donor--a pilot study of a full haplotype mismatch transplantationDiabetic ketoacidosis at diagnosis influences complete remission after treatment with hematopoietic stem cell transplantation in adolescents with type 1 diabetesHematopoietic stem cell transplantation across major genetic barriers: tolerance induction by megadose CD34 cells and other veto cells.Immunological applications of stem cells in type 1 diabetes.Human iPS cell-derived hematopoietic progenitor cells induce T-cell anergy in in vitro-generated alloreactive CD8(+) T cellsHaploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States.Microchimerism in promoting graft acceptance in clinical transplantation.New strategies for haploidentical transplantation.Current and future approaches to treat graft failure after allogeneic hematopoietic stem cell transplantation.The role of donor-derived veto cells in nonmyeloablative haploidentical HSCT.T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells.The evolution of T-cell depletion in haploidentical stem-cell transplantation.Unrelated peripheral blood stem cell transplantation with 'megadoses' of purified CD34+ cells in three children with refractory severe aplastic anemia.Transplantation of highly purified CD34+ progenitor cells from alternative donors in children with refractory severe aplastic anaemia.The use of hematopoietic stem cells in autoimmune diseases.Targeting the CXCR4-CXCL12 axis mobilizes autologous hematopoietic stem cells and prolongs islet allograft survival via programmed death ligand 1.The use of donor-derived veto cells in hematopoietic stem cell transplantation.Cooking up tolerance: has a new recipe been created?Overcoming the barriers to umbilical cord blood transplantation.High-dose peripheral blood stem cell infusion: a strategy to induce donor-specific hyporesponsiveness to allografts in pediatric renal transplant recipients.Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas.Haploidentical related-donor hematopoietic cell transplantation in children using megadoses of CliniMACs-selected CD34(+) cells and a fixed CD3(+) dose.Multilineage hematopoietic engraftment after allogeneic peripheral blood stem cell transplantation without conditioning in SCID patients.Haplotype mismatched transplantation using high doses of peripheral blood CD34+ cells together with stratified conditioning regimens for high-risk adult acute myeloid leukemia patients: a pilot study in a single Korean institution.Exercising 'veto' power to make haploidentical hematopoietic stem cell transplantation a safe modality for induction of immune tolerance.iNKT cell activation plus T-cell transfer establishes complete chimerism in a murine sublethal bone marrow transplant model.In-vivo or ex-vivo T cell depletion or both to prevent graft-versus-host disease after hematopoietic stem cell transplantation.
P2860
Q26745527-7240516C-880C-4CBD-A5E2-7EC916F16DC0Q26797506-DB93C434-0F91-437F-851F-EC5B76803F46Q27014857-D83F0C33-41E7-4DC0-BFB4-4C764A31F3C1Q27030355-C9410714-454F-48AA-AE76-5E56E96B0545Q33661926-19938368-7766-4867-8B02-40A70A802139Q33722672-BEF03EB1-35F4-4F6C-A489-26475B666DC0Q33986118-BBEADA26-8D41-4021-BA0F-C4285121ADC2Q34219866-A449AB8F-8E4A-460C-AEDF-7DB9D1AD2D00Q34255634-C2014760-ABC7-47B9-8AA5-3EB62CB9545CQ34326710-1530F912-FE8A-45E8-8A7D-95D66963A6F8Q34616704-3C657516-CC3A-4023-8D96-D0873C6A9BFDQ35692616-66281B5D-A86B-4097-B42F-76A63A6B701BQ35743914-A138BC94-61A5-4FD8-B199-D44601BD7D1EQ35936963-2EE45004-8EBF-431B-9238-32C896E6269EQ36047307-A7EC6D75-2A67-40B6-AD4E-F355229E6FE9Q36164487-04D485D0-5A61-4B7E-8EF6-114C794520BDQ36666422-060CF7F1-B9BB-4852-8CD9-A51C9E4F9C6FQ36962670-A155528F-2D58-45A6-90AF-1E122E52D1FCQ37051052-CCC2F35D-C0C7-47F8-9527-57A620BEC90BQ37888423-0D8B5D55-6BA9-465D-938F-B811AF8F0236Q37978777-FB82AC2F-2EED-4688-87E0-047432CCD511Q38155240-2551A08B-F82D-4F5F-AC71-B7E984F46259Q38514485-53A6B5C7-6D36-4ED5-A028-1033DDA5A3DCQ38514497-88D38584-B61F-4805-AC93-CAB0842B8D10Q38673780-F47C18EA-2588-4851-9B81-2053F3AA94E8Q39531190-ECB04EE0-EC01-431B-836B-7A4536D993A3Q39678480-E1305421-0313-4F8B-B88C-3CB6F78EB9F5Q39777434-8C4B0264-BB8B-4421-984F-95BD8BF6E3B2Q41964589-BBE27850-97DA-4645-B81D-F6C0922CE51AQ42144054-61DA03C2-DF71-484C-9957-A974F945FD8FQ42398792-5B18E027-CA3B-49F8-ADA7-FA1B5B2F46FFQ42974699-0A1493CC-545A-4A98-988D-613D68D09AEAQ43925397-8CCDED02-7D29-474C-B8B2-FA5D1003C947Q44119537-08EE62C8-71E6-4C1B-95DB-064DD8EE3D3EQ44362302-8F33F58B-3285-4C9F-BAB2-46920707A1A6Q44954458-0A0BED7F-7185-4C1B-ADE1-54709091E879Q46391452-4C395CC6-A0E5-4844-8B5B-42F294EE1A16Q48039446-9C06B4DA-433D-4A19-8587-DB090380E010Q48306919-1C826BEC-D47F-4207-87DD-F11F5559341BQ48680865-D95BE870-ADB5-459D-8580-BA569715E8D2
P2860
Tolerance induction by "megadose" hematopoietic transplants: donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Tolerance induction by "megado ...... s in mixed lymphocyte culture.
@en
Tolerance induction by "megado ...... s in mixed lymphocyte culture.
@nl
type
label
Tolerance induction by "megado ...... s in mixed lymphocyte culture.
@en
Tolerance induction by "megado ...... s in mixed lymphocyte culture.
@nl
prefLabel
Tolerance induction by "megado ...... s in mixed lymphocyte culture.
@en
Tolerance induction by "megado ...... s in mixed lymphocyte culture.
@nl
P2093
P1433
P1476
Tolerance induction by "megado ...... rs in mixed lymphocyte culture
@en
P2093
M Martelli
N Rachamim
R Krauthgamer
P304
P356
10.1097/00007890-199805270-00017
P50
P577
1998-05-01T00:00:00Z